U Rwanda ruriku isonga mu kuba igicumbi cy’akarere mu gukora inkingo no guhanga ibishya mu buvuzi, bitewe n’icyerekezo gikomeye cya guverinoma, kandi ku nkunga y’Umuryango w’Ubumwe bw’Ibihugu by’Uburayi binyuze mu ngamba ya Global Gateway. Ishoramari mu iterambere ry’abantu aho abantu bafite ubuzima buzira umuze baba ku mubumbe uzira umuze ari cyo kintu cy’ingenzi kuri Global Gateway.
Muri iki gihe Afurika itunzwe cyane n’uruhererekane rw’ibiva ahandi ku isi, itumiza 99% by’inkingo zayo ndetse n’ibirenga 90% by’imiti ikoresha. Ariko ishoramari mu Rwanda ririmo gutanga inzira yo kwihaza mu buvuzi, rihindura ubuvuzi ku mugabane w’Afurika no kuzana ibisubizo bya bimwe mu bibazo by’ubuzima bw’Afurika biturutse mu karere ubwako.
Mu buryo bwa Team Europe, Umuryango w’Ubumwe bw’Ibihugu by’Uburayi n’ibihugu biwugize, birimo Ubudage, Ububiligi, Ubufaransa, Lituwaniya, Suwede na Otirishe, bimaze gufatanya n’u Rwanda mu bijyanye n’imari na tekiniki.
Gushyiraho ibidukikije bikwiye
Binyuze muri Team Europe Initiative on Manufacturing and Access to Vaccines, Medicines and Health Technologies in Africa (ku bijyanye no gukora no kugera ku nkingo, imiti n’ikoranabuhanga ry’ubuzima muri Afurika ('MAV+') Umuryango w’Ubumwe bw’Ibihugu by’Uburayi utera inkunga ikorwa ryayo mu Rwanda mu rwego rw’akarere k’Afurika.
Intego y’ubufatanye ni ugushyiraho urusobe rw’ibinyabuzima kugira ngo inganda zikoresha ibinyabuzima zitere imbere.
Ibi bikubiyemo uburyo bunoze bwo kugenzura, ubufatanye bugezweho bwa R&D, imbaraga za biotech zo guhanga ibishya hamwe n’abantu bafite ubumenyi bukwiye kugira ngo ishoramari ryigenga rigende neza.
Mu Rwanda, MAV+ ishyigikira umugenzuzi w’igihugu, Ikigo cy’Ibiribwa n’Imiti mu Rwanda, kugira ngo kigenzure neza isoko no kurinda ubuziranenge n’umutekano w’ibicuruzwa binyuze mu gutanga ibikoresho bya laboratwari no kongera ubushobozi.
Kigali, umurwa mukuru w’igihugu, yiteguye kwakira icyicaro cy’Ikigo Nyafurika Gishinzwe Imiti African Medicines Agency (AMA).
Itsinda ry’Uburayi n’Ikigo cy’Ubuvuzi cy’Uburayi (Team Europe and the European Medicines Agency) bakorana cyane n’abafatanyabikorwa b’Afurika nka Komisiyo y’Umuryango w’Ubumwe bw’Afurika na AUDA-NEPAD mu rwego rwo gushyigikira ishyirwaho rya AMA neza.
Kongera ubumenyi n’akazi
MAV+ ikora kandi ku buryo igihugu kigira ibikoresho bihagije kugira ngo gitange abakozi bakenewe mu nganda mu gihe giciriritse. Ibi birimo gutangiza amasomo mashya y’icyiciro cya gatatu muri gahunda y’ibinyabuzima hagati ya kaminuza y’u Rwanda ku bufatanye na kaminuza zo mu Burayi.
Izindi gahunda nyinshi z’icyiciro cya gatatu n’icya dogitora zizategurwa mu gihe cya vuba, hamwe n’ubumenyi bwa tekiniki n’imyuga n’amahugurwa (TVET) y’abakozi bo mu nshingano zunganira abandi.
Guteza imbere ubushakashatsi no guhanga ibishya
Iyi gahunda kandi izongerera ubushobozi ubushakashatsi n’iterambere ry’ibanze, harimo binyuze mu butwererane n’ibigo by’ubushakashatsi by’i Burayi ku magerageza y’imiti no gushyigikira ishyirwaho rya parike ya mbere y’ibinyabuzima mu Rwanda.
Izatunganya uburyo buboneye bwo gutangiriraho binyuze mu kwihutisha biotech n'ikigega cy'imbuto ku butwerane n'Ubudage. Kandi Ubudage na none bushyigikira guhanga imirimo mu rwego rwa farumasi binyuze mu gutanga inyigisho zo mu buryo bw’ikoranabuhanga ndetse n’ubw’imboankubone ku barangije kaminuza ndetse n’abakozi ba farumasi zitangwa na kaminuza zo mu Budage, no gushyiraho ibyihutisha biotech, guhuza ubucuruzi ndetse no kongerera ubushobozi inzego zishinzwe ubugenzuzi.
Muri rusange MAV+ yakusanyije hafi miliyoni 94 z'amayero agenewe u Rwanda na miliyari 1.3 z'amayero agenewe umugabane ku mishinga irenga 80, ishimangira ubuzima rusange buturutse muri bene bwo.
Shakisha byinshi kuri MAV+ n’ubufatanye bwa Global Gateway n’u Rwanda
Hamagara Intumwa y’Umuryango w’Ubumwe bw’Uburayi mu Rwanda: DELEGATION-RWANDA
eeas [dot] europa [dot] eu (DELEGATION-RWANDA[at]eeas[dot]europa[dot]eu)
Rwanda is a frontrunner to become a regional hub for vaccine manufacturing and medical innovation, thanks to the strong vision of the government, and with the support of the European Union through the Global Gateway strategy. Investments in human development where healthy people live on a healthy planet is a key priority of Global Gateway.
Africa is currently critically dependent on global supply chains, importing 99% of its vaccines and over 90% of its medicines. But investments in Rwanda are paving the way for medical self-sufficiency, revolutionising healthcare on the continent and bringing solutions to some of Africa’s healthcare challenges from within the region itself.
In a Team Europe approach, the European Union and its Member States, encompassing Germany, Belgium, France, Lithuania, Sweden and Austria, have already partnered with Rwanda financially and technically.
Creating the right business environment
Through the Team Europe Initiative on Manufacturing and Access to Vaccines, Medicines and Health Technologies in Africa (‘MAV+') the EU is supporting production in Rwanda for the African region.
The focus of the collaboration is the creation of a conducive ecosystem for the biotech industry to flourish.
This entails sound regulatory frameworks, cutting edge R&D partnerships, vibrant biotech innovation hubs and people with the right skills to make private sector investment successful.
In Rwanda, MAV+ supports the national regulator, the Rwanda Food and Drugs Authority, to effectively regulate the market and ensure quality and safety of products through the provision of laboratory equipment and capacity building.
Kigali, the capital of the country, is poised to host the headquarters of the African Medicines Agency (AMA).
Team Europe and the European Medicines Agency are working closely with African partners such as the African Union Commission and AUDA-NEPAD to support the effective establishment of the AMA.
Boosting skills and jobs
MAV+ also ensures that the country is well equipped to provide the necessary workforce for the industry in the medium term. This includes the launch of a new MSc in Biotechnology programme between the University of Rwanda in partnership with European universities.
More MSc and PhD programmes will be developed in the near future, as well as technical and vocational education and training (TVET) paths for staff in support roles.
Fostering research and innovation
The initiative will also strengthen local research and development, including through cooperation with European research institutes on clinical trials and support to the set-up of the first Biosciences Park in Rwanda.
It will nurture the right environment for start-ups through a biotech accelerator and seed fund in cooperation with Germany. And Germany is also supporting job creation in the pharma sector through the provision of blended learning to university graduates and pharma employees by German universities, the set-up of a biotech accelerator, business-to-business matchmaking and capacity building for the regulatory authorities.
In total MAV+ has mobilised close to €94 million for Rwanda and €1.3 billion for the continent for more than 80 projects, strengthening collective health from within.
Find out more about MAV+ and the Global Gateway partnership with Rwanda
Contact the EU Delegation to Rwanda: DELEGATION-RWANDAeeas [dot] europa [dot] eu (DELEGATION-RWANDA[at]eeas[dot]europa[dot]eu)
